Skip Navigation

A Phase II Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway?Mutant Acute Lymphoblastic Leukemia

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02723994

Study #:
CMH - AALL1521

Start Date:
Feb 23, 2017

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02723994

View Complete Trial Details & Eligibility at ClinicalTrials.gov